332 related articles for article (PubMed ID: 32669298)
1. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
Aeppli S; Eboulet EI; Eisen T; Escudier B; Fischer S; Larkin J; Gruenwald V; McDermott D; Oldenburg J; Omlin A; Porta C; Rini B; Schmidinger M; Sternberg C; Rothermundt C
ESMO Open; 2020 Jul; 5(Suppl 3):. PubMed ID: 32669298
[TBL] [Abstract][Full Text] [Related]
2. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
Ghosh N; Tirpack A; Chan KK; Bass AR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.
Aeppli S; Schmaus M; Eisen T; Escudier B; Grünwald V; Larkin J; McDermott D; Oldenburg J; Porta C; Rini BI; Schmidinger M; Sternberg CN; Rothermundt C; Putora PM
ESMO Open; 2021 Feb; 6(1):100030. PubMed ID: 33460963
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
5. Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
Ürün Y; Hussain SA; Bakouny Z; Castellano D; Kılıçkap S; Morgan G; Mckay RR; Pels K; Schmidt A; Doroshow DB; Schütz F; Albiges L; Lopes G; Catto JWF; Peters S; Choueiri TK
JCO Glob Oncol; 2020 Aug; 6():1248-1257. PubMed ID: 32755479
[TBL] [Abstract][Full Text] [Related]
6. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for metastatic renal cell carcinoma.
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
[TBL] [Abstract][Full Text] [Related]
8. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Epaillard N; Simonaggio A; Elaidi R; Azzouz F; Braychenko E; Thibault C; Sun CM; Moreira M; Oudard S; Vano YA
Bull Cancer; 2020 Jun; 107(5S):eS22-eS27. PubMed ID: 32620212
[TBL] [Abstract][Full Text] [Related]
9. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
[TBL] [Abstract][Full Text] [Related]
10. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Ottaviano M; Curvietto M; Rescigno P; Tortora M; Palmieri G; Giannarelli D; Aieta M; Assalone P; Attademo L; Avallone A; Bloise F; Bosso D; Borzillo V; Buono G; Calderoni G; Caputo F; Cartenì G; Cavallero D; Cavo A; Ciardiello F; Conca R; Conteduca V; De Falco S; De Felice M; De Laurentiis M; De Placido P; De Placido S; De Santo I; De Stefano A; Della Corte CM; Di Franco R; Di Lauro V; Fabbrocini A; Federico P; Festino L; Giordano P; Giuliano M; Gridelli C; Grimaldi AM; Lia M; Marretta AL; Massa V; Mennitto A; Merler S; Merz V; Messina C; Messina M; Milano M; Minisini AM; Montesarchio V; Morabito A; Morgillo F; Mucci B; Nappi L; Napolitano F; Paciolla I; Pagliuca M; Palmieri G; Parola S; Pepe S; Petrillo A; Piantedosi F; Piccin L; Picozzi F; Pietroluongo E; Pignata S; Prati V; Riccio V; Rosanova M; Rossi A; Russo A; Salati M; Santabarbara G; Sbrana A; Simeone E; Silvestri A; Spada M; Tarantino P; Taveggia P; Tomei F; Vincenzo T; Trapani D; Trojanello C; Vanella V; Vari S; Ventriglia J; Vitale MG; Vitiello F; Vivaldi C; von Arx C; Zacchi F; Zampiva I; Zivi A; Daniele B; Ascierto PA;
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.
Mihalopoulos M; Dogra N; Mohamed N; Badani K; Kyprianou N
Eur Urol Focus; 2020 Sep; 6(5):1086-1096. PubMed ID: 32540268
[TBL] [Abstract][Full Text] [Related]
12. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
13. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.
Yan X; Zhou L; Li S; Wu X; Cui C; Chi Z; Si L; Kong Y; Tang B; Li C; Mao L; Wang X; Lian B; Bai X; Dai J; Guo J; Sheng X
Clin Genitourin Cancer; 2022 Aug; 20(4):354-362. PubMed ID: 35387755
[TBL] [Abstract][Full Text] [Related]
14. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
Albiges L; Powles T; Staehler M; Bensalah K; Giles RH; Hora M; Kuczyk MA; Lam TB; Ljungberg B; Marconi L; Merseburger AS; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Bex A
Eur Urol; 2019 Aug; 76(2):151-156. PubMed ID: 31151678
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
[TBL] [Abstract][Full Text] [Related]
16. Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms.
Rothermundt C; von Rappard J; Eisen T; Escudier B; Grünwald V; Larkin J; McDermott D; Oldenburg J; Porta C; Rini B; Schmidinger M; Sternberg CN; Putora PM
World J Urol; 2017 Apr; 35(4):641-648. PubMed ID: 27488984
[TBL] [Abstract][Full Text] [Related]
17. Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic.
Chen Y; Hu S; Wu H; Farraye FA; Bernstein CN; Zheng JJ; Kiran RP; Shen B
Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):632-634. PubMed ID: 32411921
[No Abstract] [Full Text] [Related]
18. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
[TBL] [Abstract][Full Text] [Related]
20. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
